Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | EIF4E | P06730 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309293 | 0.87 | NOTUM (0.45) | KCNH2ARTRPA1IDO1NPC1 | |
| SCHEMBL1220445 | 0.87 | KCNH2 (0.51) | KCNH2EIF4ECACNA1G | |
| SCHEMBL3721862 | 0.86 | CACNA1G (0.42) | KCNH2NPC1RAB9ACACNA1GPDE3B | |
| SCHEMBL3721640 | 0.86 | KCNH2 (0.39) | KCNH2NPC1RAB9ACACNA1G | |
| SCHEMBL1220435 | 0.82 | MAPT (0.41) | NPC1RAB9AEIF4E | |
| SCHEMBL3723404 | 0.82 | GPR3 (0.37) | KCNH2NPC1RAB9ACACNA1G | |
| SCHEMBL3724820 | 0.80 | LMNA (0.41) | KCNH2ARNPC1RAB9A | |
| SCHEMBL1220433 | 0.79 | ALDH1A1 (0.36) | KCNH2NPC1RAB9ACACNA1GHSD11B1 | |
| SCHEMBL5332136 | 0.79 | IDO1 (0.38) | KCNH2ARTRPA1IDO1NPC1 | |
| SCHEMBL1221395 | 0.79 | NPC1 (0.36) | NPC1RAB9ACACNA1GCNR2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242983-B2 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-26 | — | — | US | disclosed |
| US-9242983-B2 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-26 | — | — | US | disclosed |
| US-9242983-B2 | Viral inhibitors | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-26 | — | — | US | disclosed |
| EP-2094702-B1 | VIRAL INHIBITORS | GILEAD SCIENCES INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2094702-B1 | VIRAL INHIBITORS | GILEAD SCIENCES INC (US) | 2015-09-02 | — | — | EP | disclosed |
| CN-101538267-B | Imidazo [4,5-c ] pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV | 2015-04-29 | — | — | CN | disclosed |
| US-20140221382-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221382-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221382-A1 | VIRAL INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8722677-B2 | Viral inhibitors | GILEAD SCIENCES, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20080207678-A1 | Propylaxic or therapy of viral infections; using pyrrolo( 2,3-c)pyridine | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207678-A1 | Propylaxic or therapy of viral infections; using pyrrolo( 2,3-c)pyridine | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080207678-A1 | Propylaxic or therapy of viral infections; using pyrrolo( 2,3-c)pyridine | GILEAD SCIENCES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| CN-1902198-A | Imidazo [4, 5-c ] pyridine compounds and methods of antiviral treatment | K U LEUVEN RES & DEV GERHARD P (BE) | 2007-01-24 | — | — | CN | disclosed |
| EP-1706403-A2 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U.Leuven Research & Development (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207678-A1 | Propylaxic or therapy of viral infections; using pyrrolo( 2,3-c)pyridine | PNPO, PRDX6, PRDX4 | KCNH2 2847/4885AR 2923/4885TRPA1 4466/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | KCNH2 1346/4885AR 4328/4885TRPA1 3904/4885 |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | CYP3A5, TPMT, TYMP | KCNH2 1866/4885AR 3409/4885TRPA1 3853/4885 |
| US-20140221382-A1 | VIRAL INHIBITORS | ZC3HAV1, DDX5, ZC3HAV1L | KCNH2 3302/4885AR 2679/4885TRPA1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.